CO7121334A2 - Formulaciones vesiculares - Google Patents
Formulaciones vesicularesInfo
- Publication number
- CO7121334A2 CO7121334A2 CO14238690A CO14238690A CO7121334A2 CO 7121334 A2 CO7121334 A2 CO 7121334A2 CO 14238690 A CO14238690 A CO 14238690A CO 14238690 A CO14238690 A CO 14238690A CO 7121334 A2 CO7121334 A2 CO 7121334A2
- Authority
- CO
- Colombia
- Prior art keywords
- vesicular
- vesicular formulations
- formulations
- rosacea
- refers
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241001303601 Rosacea Species 0.000 abstract 2
- 201000004700 rosacea Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1205642.0A GB201205642D0 (en) | 2012-03-29 | 2012-03-29 | Vesicular formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7121334A2 true CO7121334A2 (es) | 2014-11-20 |
Family
ID=46159988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14238690A CO7121334A2 (es) | 2012-03-29 | 2014-10-28 | Formulaciones vesiculares |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9555051B2 (enExample) |
| EP (1) | EP2830630A1 (enExample) |
| JP (1) | JP2015511618A (enExample) |
| KR (1) | KR20150004798A (enExample) |
| CN (1) | CN104349782A (enExample) |
| AU (1) | AU2013241701A1 (enExample) |
| BR (1) | BR112014024033A8 (enExample) |
| CA (1) | CA2867749A1 (enExample) |
| CL (1) | CL2014002547A1 (enExample) |
| CO (1) | CO7121334A2 (enExample) |
| EA (1) | EA038899B1 (enExample) |
| GB (2) | GB201205642D0 (enExample) |
| IL (1) | IL234747A0 (enExample) |
| IN (1) | IN2014DN07913A (enExample) |
| MX (1) | MX2014011516A (enExample) |
| NZ (1) | NZ700472A (enExample) |
| PH (1) | PH12014502065A1 (enExample) |
| SG (1) | SG11201406144TA (enExample) |
| WO (1) | WO2013144289A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2486371A (en) | 2009-08-21 | 2012-06-13 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| AU2015370922B2 (en) * | 2014-12-23 | 2018-10-04 | Camurus Ab | Controlled-release formulations |
| US10744090B2 (en) | 2015-06-30 | 2020-08-18 | Sequessome Technology Holdings Limited | Multiphasic compositions |
| EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| US20240299378A1 (en) * | 2021-02-25 | 2024-09-12 | Exinov | Emulsion for use in the treatment of rosacea |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60136511A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 高尿酸血症治療剤 |
| EP0238554A4 (en) | 1985-09-27 | 1987-10-27 | Univ California | SYSTEM FOR TRANSDERMAL DELIVERY OF MEDICAMENTS TO LIPOSOMES. |
| JPS6295134A (ja) | 1985-10-21 | 1987-05-01 | Nippon Saafuakutanto Kogyo Kk | リポソ−ムの製造法 |
| US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5498607A (en) | 1990-07-30 | 1996-03-12 | University Of Miami | Treatment for hypercholesterolemia |
| JP3765579B2 (ja) | 1990-08-24 | 2006-04-12 | イーデーエーアー アーゲー | 作用物質投与用超微小滴状調剤 |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| JPH08509202A (ja) | 1992-07-08 | 1996-10-01 | ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リポソーム、それを調製する方法及び薬調製におけるその用途 |
| FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| FR2767691B1 (fr) | 1997-08-27 | 2000-02-18 | Oreal | Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire |
| SK284338B6 (sk) * | 1997-11-19 | 2005-02-04 | Schering Aktiengesellschaft | Kompozícia s kyselinou azelaínovou |
| US6165997A (en) | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
| CN1322129A (zh) | 1998-09-01 | 2001-11-14 | 伊迪亚股份公司 | 带电穿透剂通过屏障的电控转运 |
| CZ20012038A3 (cs) | 1998-12-23 | 2001-09-12 | Idea Ag | Zdokonalený přípravek pro topické, neinvazivní použití in vivo |
| EP1031346B1 (en) | 1999-01-27 | 2002-05-02 | Idea Ag | Noninvasive vaccination through the skin |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| WO2001001962A1 (en) | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| US6248728B1 (en) | 2000-03-10 | 2001-06-19 | Kansas State University Research Foundation | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
| US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| DK1272160T3 (da) | 2000-04-12 | 2007-05-21 | Liplasome Pharma As | Lipidbaseret lægemiddelleveringssystem til topisk applikation |
| TWI281407B (en) | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| WO2002062316A1 (de) | 2001-02-08 | 2002-08-15 | Vectron Therapeutics Ag | Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung |
| WO2002096435A2 (en) | 2001-05-31 | 2002-12-05 | Pharmacia Corporation | Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol |
| JP2004535434A (ja) | 2001-06-25 | 2004-11-25 | デピユイ | 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化 |
| CA2368656A1 (en) | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| AU2003233396B2 (en) | 2002-03-13 | 2007-05-24 | Thomas Skold | Water-based delivery systems |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| NZ538571A (en) | 2002-10-11 | 2007-05-31 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| JP2004131432A (ja) | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
| AU2004235781A1 (en) | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| WO2005007169A2 (en) | 2003-07-21 | 2005-01-27 | Vasogen Ireland Limited | Liposomes containing phosphate glycerol groups for treating acute inflammatory condition |
| JP2005179313A (ja) * | 2003-12-24 | 2005-07-07 | Shu Uemura:Kk | 皮膚化粧料用基剤の製造方法および皮膚化粧料 |
| US7476432B2 (en) | 2004-05-28 | 2009-01-13 | Tecton Products | Phosphorescent pultrusion |
| CA2584475A1 (en) | 2004-11-12 | 2006-05-18 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
| WO2006086992A2 (en) | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| US20070042008A1 (en) | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
| BRPI0615411A2 (pt) | 2005-08-29 | 2012-12-04 | Sepsicure L L C | uso de um ácido da bìlis ou de um sal de ácido da bìlis e um fosfolipìdeo |
| EP1968567B1 (en) | 2005-12-20 | 2014-06-18 | Cenestra, Llc | Omega 3 fatty acid formulations |
| JP5009547B2 (ja) * | 2006-03-31 | 2012-08-22 | 株式会社コーセー | 顔料とリポソームを含む化粧料 |
| US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
| CA2664944C (en) | 2006-09-28 | 2016-06-14 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
| JP4732307B2 (ja) | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
| US20100130611A1 (en) | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
| EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
| ITVR20080006A1 (it) | 2008-01-23 | 2009-07-24 | David Ceretta | Apparato per la realizzazione di elementi d'impasto |
| ES2335636B1 (es) | 2008-02-29 | 2011-05-11 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica de micelas mixtas. |
| JP2009256331A (ja) | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
| US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| CA2751412A1 (en) | 2009-02-05 | 2010-08-12 | Targeted Delivery Technologies Limited | Methods of reducing the proliferation and viability of microbial agents |
| JP2012528846A (ja) | 2009-06-03 | 2012-11-15 | マヨ、ジョン、チャールズ | 深部組織の痛みを治療するための製剤 |
| GB2486371A (en) | 2009-08-21 | 2012-06-13 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| EP2382994A1 (en) | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| US20120045405A1 (en) | 2010-08-18 | 2012-02-23 | Gilman Miles E | Under eye cream |
| GB201206486D0 (en) | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| GB201208409D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
| GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
| SG11201600424VA (en) | 2013-07-31 | 2016-02-26 | Sequessome Technology Holdings Ltd | Vesicles |
-
2012
- 2012-03-29 GB GBGB1205642.0A patent/GB201205642D0/en not_active Ceased
-
2013
- 2013-03-28 IN IN7913DEN2014 patent/IN2014DN07913A/en unknown
- 2013-03-28 MX MX2014011516A patent/MX2014011516A/es unknown
- 2013-03-28 AU AU2013241701A patent/AU2013241701A1/en not_active Abandoned
- 2013-03-28 US US14/388,469 patent/US9555051B2/en not_active Expired - Fee Related
- 2013-03-28 JP JP2015502351A patent/JP2015511618A/ja active Pending
- 2013-03-28 EA EA201491581A patent/EA038899B1/ru unknown
- 2013-03-28 NZ NZ700472A patent/NZ700472A/en not_active IP Right Cessation
- 2013-03-28 KR KR1020147027498A patent/KR20150004798A/ko not_active Withdrawn
- 2013-03-28 WO PCT/EP2013/056694 patent/WO2013144289A1/en not_active Ceased
- 2013-03-28 SG SG11201406144TA patent/SG11201406144TA/en unknown
- 2013-03-28 CN CN201380027033.9A patent/CN104349782A/zh active Pending
- 2013-03-28 GB GB1419075.5A patent/GB2515440B/en not_active Expired - Fee Related
- 2013-03-28 CA CA2867749A patent/CA2867749A1/en not_active Abandoned
- 2013-03-28 BR BR112014024033A patent/BR112014024033A8/pt not_active IP Right Cessation
- 2013-03-28 EP EP13712801.3A patent/EP2830630A1/en not_active Ceased
-
2014
- 2014-09-17 PH PH12014502065A patent/PH12014502065A1/en unknown
- 2014-09-18 IL IL234747A patent/IL234747A0/en unknown
- 2014-09-25 CL CL2014002547A patent/CL2014002547A1/es unknown
- 2014-10-28 CO CO14238690A patent/CO7121334A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201205642D0 (en) | 2012-05-16 |
| EA038899B1 (ru) | 2021-11-03 |
| BR112014024033A8 (pt) | 2017-07-25 |
| CA2867749A1 (en) | 2013-10-03 |
| BR112014024033A2 (enExample) | 2017-06-20 |
| US9555051B2 (en) | 2017-01-31 |
| EP2830630A1 (en) | 2015-02-04 |
| NZ700472A (en) | 2016-02-26 |
| CL2014002547A1 (es) | 2015-03-27 |
| GB2515440A (en) | 2014-12-24 |
| IN2014DN07913A (enExample) | 2015-04-24 |
| IL234747A0 (en) | 2014-11-30 |
| GB201419075D0 (en) | 2014-12-10 |
| AU2013241701A1 (en) | 2014-10-16 |
| GB2515440B (en) | 2017-02-08 |
| WO2013144289A1 (en) | 2013-10-03 |
| KR20150004798A (ko) | 2015-01-13 |
| MX2014011516A (es) | 2015-04-08 |
| EA201491581A1 (ru) | 2015-02-27 |
| PH12014502065A1 (en) | 2014-12-10 |
| JP2015511618A (ja) | 2015-04-20 |
| US20150057249A1 (en) | 2015-02-26 |
| SG11201406144TA (en) | 2014-10-30 |
| CN104349782A (zh) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
| MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
| MX372669B (es) | Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer. | |
| MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20151067A1 (es) | Inhibidores de autotaxina | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| MX2015006337A (es) | Metodos y composiciones para tratar enfermedades neurodegenerativas. | |
| CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| BR112017007916A2 (pt) | compostos sarms para tratamento de distúrbios urológicos | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| CR20160227A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| GT201500124A (es) | Forma sòlida de un derivado de dihidro-pirido-oxazina |